YORK, Sept. 2, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Humanigen, Inc. (NASDAQ:
To receive updates on the lawsuit, fill out the
The lawsuit seeks to recover losses for shareholders who
purchased Humanigen between May 28,
2021 and July 12, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
October 25, 2022 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, Humanigen, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) Humanigen's lead product candidate, lenzilumab,
was less effective in treating hospitalized COVID-19 patients than
defendants had represented; (ii) as a result, the U.S. Food and
Drug Administration was unlikely to approve the lenzilumab
Emergency Use Authorization and the ACTIV-5/BET-B study was
unlikely to meet its primary endpoint; (iii) accordingly,
lenzilumab's clinical and commercial prospects were overstated; and
(iv) as a result, the Company's public statements were materially
false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE Jakubowitz Law